Renalytix's Q3 2024 earnings transcript might seem like a familiar refrain to those who have been following the company. Cost reductions, a renewed focus on sales, and the ever-present promise of widespread adoption of KidneyIntelX. But beneath the surface, a subtle shift is occurring, one that could be signaling a dramatic inflection point for the company. This change has flown under the radar of most analysts, but it holds the key to unlocking Renalytix's true potential.

The game changer is not the much-anticipated Medicare Local Coverage Determination, nor the inclusion of KidneyIntelX in international clinical guidelines. It's the quiet emergence of the direct-to-physician sales channel as a dominant force. While the company has long spoken of the importance of this channel, the latest transcript reveals just how potent this strategy has become.

For the first time, the direct sales force, composed of experienced diagnostic industry professionals, has achieved a 33% increase in test order rates quarter-over-quarter. More importantly, this growth is continuing into the current fiscal quarter. This isn't just a blip; it's a sustained trend indicating that Renalytix has finally found the formula to unlock primary care physician adoption. (

Reference)

Remember, the biggest hurdle for Renalytix has always been getting primary care physicians to integrate KidneyIntelX into their busy workflow. The test, while proven effective and valuable, requires physicians to identify appropriate patients and navigate insurance procedures, creating friction in a fast-paced environment. Previous strategies, like relying on large health systems to drive adoption, proved cumbersome and slow.

But the direct sales approach is nimble and targeted. These sales professionals are on the ground, building relationships with individual physicians, educating them on the benefits of KidneyIntelX, and helping them overcome the hurdles to implementation. They are the boots on the ground, driving adoption at the granular level, one doctor at a time. (

Reference)

The 33% quarter-over-quarter growth is a testament to the effectiveness of this strategy. It represents a fundamental shift in the adoption dynamic, signaling a break from the slow, cumbersome pace of the past. Consider this: Renalytix reported 806 tests processed in Q3, with 82% billable. This translates to roughly 660 billable tests. Howard Doran, the company's President, disclosed that 40% of these tests were driven by the direct sales team. (

Reference)

This means that a small, focused sales team of around 10 individuals generated approximately 264 tests in a single quarter. Extrapolating this performance to a full year, assuming even modest growth, paints a picture of significant revenue generation.

Direct Sales Force Performance

Let's be conservative and assume each sales representative drives 300 billable tests annually. With 10 reps, that's 3,000 tests at $950 each, translating to $2.85 million in annual revenue. Now, factor in the company's stated intention to expand the sales force, even by a small amount, and the revenue potential starts to look quite compelling.

Furthermore, this doesn't account for the anticipated growth from health system partnerships like Atrium Wake Forest, which are expected to add significant volume once fully implemented. It also doesn't account for the likely increase in reimbursement coverage driven by the pending LCD and KidneyIntelX's inclusion in clinical guidelines.

Revenue Projection Based on Direct Sales Force

The following chart illustrates the potential revenue generation from the direct sales force, assuming a conservative estimate of 300 billable tests per sales representative annually.

The bottom line is this: Renalytix is on the cusp of a major breakthrough. Wall Street, fixated on the big-picture events like the LCD and guidelines, is missing the real story unfolding at the ground level. The direct-to-physician sales strategy is working, and it's working well.

The numbers don't lie. With a disciplined cost structure, a proven product, and a highly effective sales model, Renalytix is poised to unlock a multi-billion dollar market. This quiet revolution in the company's sales strategy may be the catalyst that transforms Renalytix from a promising startup to a dominant force in the kidney diagnostics space.

"Fun Fact: Did you know that chronic kidney disease affects 15% of US adults, or 37 million people? That's more than the entire population of Canada! And 9 in 10 adults with CKD don't even know they have it. Renalytix is addressing a silent epidemic with a game-changing solution."